logo
  

Stock Alert: Foley Trasimene Acquisition Touches New 52-week High

Shares of Foley Trasimene Acquisition Corp. II (BFT), a special purpose acquisition company, are gaining more than 5 percent or $0.88 in Thursday's morning trade at $18.35. The shares earlier hit a new 52-week high of $18.65 despite no company-centric news.

In early December, Foley Trasimene and Paysafe Group Holdings Limited, an integrated payments platform, said they have entered into a definitive agreement and plan of merger. The transaction reflects an implied pro-forma enterprise value for Paysafe of about $9 billion.

The transaction is expected to close in the first half of 2021. Upon closing of the transaction, the newly combined company will operate as Paysafe and plans to list on the New York Stock Exchange under the symbol "PSFE".

Foley Trasimene Acquisition has traded in a range of $9.60 to $18.65 in the past 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Looking to Invest in the Best Biotech Stocks? Subscribe to RTT Biotech Investor.
Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT